Recombinant human insulin - Sanofi

Drug Profile

Recombinant human insulin - Sanofi

Alternative Names: HR 1799; Insulin HPR; Insulin Human Winthrop; Insuman; Insuman Comb 25; Insuman Implantable

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hoechst Marion Roussel Deutschland GmbH
  • Developer Sanofi
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 01 Feb 2018 Sanofi completes a phase III trial for Type-1 diabetes mellitus in Belgium, France, Netherlands and Sweden (Intraperitoneal) (NCT01194882)
  • 23 Mar 2015 No recent reports on development identified - Phase-III for Type-2 diabetes mellitus in China (SC)
  • 25 Jul 2013 The CHMP recommends approval of Recombinant human insulin (Intraperitoneal) for Type-1 diabetes mellitus in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top